Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19816871 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8441499 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8811913 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL415770 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8814164 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL7201423 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL436881 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL274488 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL1976573 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8812283 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024177860-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2024-08-29 | — | — | WO | claimed |
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | GENOMATICA, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12559784-B2 | In chemico test for toxicity | LEBRUN LABS LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250369032-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250188501-A1 | SEMISYNTHETIC ROUTES TO ORGANIC COMPOUNDS | AGAIN BIO APS (DK) | 2025-06-12 | — | — | US | disclosed |
| US-20250101489-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC | 2025-03-27 | — | — | US | disclosed |
| US-20250019731-A1 | Methods Of Producing Omega-Hydroxylated Fatty Acid Derivatives | AGAIN BIO APS (DK) | 2025-01-16 | — | — | US | disclosed |
| US-12188068-B2 | Semisynthetic routes to organic compounds | GENOMATICA, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024177860-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-118460487-A | Process for producing OMEGA-hydroxylated fatty acid derivatives | 基因组股份公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
| US-20050154221-A1 | Integrate chemical processes for industrial utilization of seed oils | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2005-07-14 | — | — | US | disclosed |
| EP-1501784-A1 | INTERGRATED CHEMICAL PROCESSES FOR INDUSTRIAL UTILIZATION OF SEED OILS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| CN-1510420-A | Connecting molecule combined with substrate for cnstructing | �Ҵ���˾ | 2004-07-07 | — | — | CN | disclosed |
| WO-2003093215-A1 | INTERGRATED CHEMICAL PROCESSES FOR INDUSTRIAL UTILIZATION OF SEED OILS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-6307108-B1 | SEPARATING ORGANOPHOSPHORUS LIGAND DEGRADATION PRODUCTS, REACTION BYPRODUCTS AND FORMYLESTER PRODUCTS FROM A REACTION PRODUCT FLUID COMPRISING ONE OR MORE UNREACTED UNSATURATED ESTER REACTANTS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-5756854-A | PHOSPHINE AND THODIUM CARBONYL CATALYSTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-26 | — | — | US | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | CYP4F11, CYP2F1, CYP4Z1 | LMNA 3439/4885ALDH1A1 327/4885TSHR 1330/4885 |
| US-20050154221-A1 | Integrate chemical processes for industrial utilization of seed oils | ALOX12, SQLE, ALOX15 | LMNA 1396/4885ALDH1A1 858/4885TSHR 3783/4885 |
| US-12559784-B2 | In chemico test for toxicity | ALPP, ALPI, CUTA | LMNA 3569/4885ALDH1A1 274/4885TSHR 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.